A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)

StatusActive, Not Recruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Nov 2026 to Apr 2027
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 20 of 23 entries
    • Publications: details revised at 1 of 1 entry
  2. Primary completion date changed from estimate of Jul 2026 to Jul 15, 2026v46
  3. Primary completion pushed from May 2026 to Jul 2026v45 Show 4 more changesShow less
    • Interventions: MM120 (LSD D-Tartrate) (Drug), Placebo (Other) to DT120 (Drug), Placebo (Other)
    • Secondary endpoints revised (23)
    • Study description revised
    • Study title revised
  4. Trial status changed: Recruiting → Active, Not Recruiting
    • Enrollment target: estimated 200 to confirmed 214
    • Study sites: 36 to 34
    v44
  5. Site details revised at 1 of 36 sitesv43
Show 41 earlier versionsHide 41 earlier versions
  1. Site details revised at 1 of 36 sitesv42
  2. Study sites: 37 to 36v41
  3. Study sites: 36 to 37v40
  4. Site details revised at 3 of 36 sitesv39
  5. Site details revised at 3 of 36 sitesv38
  6. Study sites: 35 to 36v37
  7. Study sites: 32 to 35v36
  8. Site details revised at 1 of 32 sitesv35
  9. Site details revised at 2 of 32 sitesv34
  10. Site details revised at 2 of 32 sitesv33
  11. Site details revised at 1 of 32 sitesv32
  12. Site details revised at 2 of 32 sitesv31
  13. Site contacts updated at 1 of 32 sitesv30
  14. Site details revised at 1 of 32 sitesv29
  15. Site details revised at 3 of 32 sitesv28
  16. Site contacts updated at 1 of 32 sitesv27
  17. Site details revised at 1 of 32 sitesv26
  18. Study sites: 29 to 32v25
  19. Study sites revised (29)v24
  20. Site details revised at 3 of 29 sitesv23
  21. Site details revised at 1 of 29 sitesv22
  22. Site details revised at 1 of 29 sitesv21
  23. Study sites: 28 to 29v20
  24. Study sites: 27 to 28v19
  25. Site contacts updated at 1 of 27 sitesv18
  26. Site details revised at 3 of 27 sitesv17
  27. Re-verified, no change to tracked fieldsv16
  28. Study sites: 26 to 27v15
  29. Site details revised at 1 of 26 sitesv14
  30. Primary completion date: May 15, 2026 to May 2026
    • Study completion date: Nov 25, 2026 to Nov 2026
    • Study description expanded, about 5 words
    v13
  31. Site contacts updated at 1 of 26 sitesv12
  32. Eligibility criteria shortened, about 31 words
    • Site details revised at 1 of 26 sites
    v11
  33. Site contacts updated at 1 of 26 sitesv10
  34. Study sites: 27 to 26v9
  35. Site details revised at 2 of 27 sitesv8
  36. Site details revised at 2 of 27 sitesv7
  37. Site details revised at 2 of 27 sitesv6
  38. Study sites: 28 to 27
    • Primary completion date: Dec 27, 2026 to May 15, 2026
    • Study completion date: Jun 3, 2027 to Nov 25, 2026
    v5
  39. Site details revised at 1 of 28 sitesv4
  40. Study sites: 7 to 28v3
  41. Study title shortened, about 12 wordsv2
  1. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Trial Details
NCT Number NCT06741228
Lead Sponsor Definium Therapeutics US, Inc.
Conditions
(from sponsor)		 Generalized Anxiety Disorder
Related terms Generalized Anxiety Disorder
Enrollment 214 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov